Recent advancements in GLP-1 weight-loss medications are being hailed as significant breakthroughs in the biotech sector over the past decade. However, mental health professionals are increasingly concerned about the potential adverse effects these drugs may have on individuals with eating disorders. A new report has revealed a staggering rise in the global prevalence of anorexia nervosa and bulimia nervosa, with estimates indicating that by 2023, around 19 million people were living with these disorders alone. Experts caution that this figure likely underrepresents the true incidence, as it excludes various other eating disorders that affect countless individuals.
Cheri Levinson, a clinical psychologist at the University of Louisville with nearly a decade of specialization in eating disorders, has observed a troubling trend: a rise in patients exhibiting more severe symptoms, many of whom misuse GLP-1 medications. Levinson notes, “This is the worst I’ve seen things.” Eating disorders, characterized by harmful eating behaviors that significantly impact physical and mental health, can be influenced by genetic predispositions, societal pressures, and stressors. The prevailing culture of thinness, exacerbated by social media, has been identified as a catalyst for these conditions.
A comprehensive study conducted by researchers at Nanjing Medical University analyzed global data on anorexia and bulimia from 2000 to 2020, revealing a 66% increase in incidence rates during this period. The report highlights the considerable toll these disorders take on global health, costing approximately 17 million years of healthy life in 2020 alone. Experts like Cynthia Bulik from the University of North Carolina emphasize that social media platforms, often inundated with images of idealized body types and diet trends, can worsen the situation for vulnerable individuals. Additionally, the COVID-19 pandemic and subsequent lockdowns have further contributed to this alarming trend, with hospitalizations for eating disorders in the U.S. doubling between 2019 and 2021. Levinson warns that the rising popularity of GLP-1 drugs could exacerbate these issues, as many people resort to them in hopes of achieving that elusive ideal, sometimes leading to dangerous misuse that could precipitate eating disorders, especially among younger populations.
Source: Eating disorders are on the rise. GLP-1s could make things worse. via MIT Technology Review